DRMA — Dermata Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne
Brief: Dermata Announces Achievement Of 50% Enrollment In Pivotal Dmt310 Phase 3 Star-1 Clinical Trial For Acne
Brief: Dermata Therapeutics says Entered Into ATM Agreement With H.C. Wainwright Providing For Sale By Co Of Its Shares Of Common Stock From Time To Time
Brief: Dermata Therapeutics Inc - On June 4 Got Letter From Nasdaq That Company Has Regained Compliance With Minimum Bid Price Requirement
Dermata Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Dermata Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Dermata Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Dermata Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: Dermata Therapeutics Enrolls First Patient In Dmt310 Phase 3 Star-1 Clinical Trial For Acne
Dermata rises on plans to begin enrollment for late-stage acne treatment study
Brief: Dermata Therapeutics To Begin Enrolling Patients In Dmt310 Phase 3 Acne Clinical Program
U.S. STOCKS ON THE MOVE-DXP Enterprises, Holley, Augmedix
U.S. STOCKS ON THE MOVE-Arlo Technologies, Old Republic, Clearmind Medicine
Dermata Therapeutics jumps as Q1 loss narrows
U.S. STOCKS ON THE MOVE-GSK, Fox Corp, First Solar
U.S. STOCKS ON THE MOVE-Blue Bird, Faraday Future, OppFi
Dermata jumps on smaller Q1 loss over last year